- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Express Scripts Stops Covering Key Big Pharma Drugs on Clinical, Cost-Effectiveness Grounds
A few weeks ago, Novo Nordisk ($NVO) said it had lost Express Scripts' business on two of its top drugs, Victoza and NovoLog. Well, that was just part of the action at the pharmacy benefits manager.
A few weeks ago, Novo Nordisk ($NVO) said it had lost Express Scripts' business on two of its top drugs, Victoza and NovoLog. Well, that was just part of the action at the pharmacy benefits manager. More than 40 other drugs, including some of Big Pharma's newest growth prospects, got the same treatment. And ironically, drugmakers may have their own marketing techniques to blame.
The PBM's National Preferred Formulary for 2014 includes a list of 44 treatments and supplies that won't be covered. Patients will be required to choose alternatives, which are helpfully listed alongside the newly excluded products. Among the excluded drugs are Pfizer's ($PFE) newly approved rheumatoid arthritis drug Xeljanz, Johnson & Johnson's ($JNJ) recently launched psoriasis treatment Stelara, and GlaxoSmithKline's ($GSK) newly minted respiratory drug Breo Ellipta.
This is the first time that Express Scripts' ($ESRX) preferred formulary designates certain drugs as "not covered," spokesman David Whitrap said in an emailed statement.
Read the full story here: http://bit.ly/GPdCcq
Source: FiercePharma
Psoriasis as an Inflammatory Disease, and What’s Changed Over Time
August 3rd 2021August is National Psoriasis Awareness Month, and on this episode of Managed Care Cast, we bring you an excerpt of an interview with a New Jersey dermatologist about the changing concept of psoriasis as more than just a skin disease.
Listen
Preventing Respiratory Illness and Death Through Tighter Air Quality Standards
June 1st 2021On this episode of Managed Care Cast, a research scholar at the Marron Institute of Urban Management at New York University discusses the latest findings in the Health of the Air report, which was presented at the recent American Thoracic Society 2021 International Conference.
Listen
Brodalumab Is Effective, Safe in Patients With Moderate to Severe Psoriasis
March 18th 2024Posters presented at the American Academy of Dermatology Annual Meeting demonstrated both short- and long-term efficacy and safety profiles of brodalumab in patients with moderate to severe psoriasis.
Read More
